loading page

Gabapentin utilization among older adults with different cognitive statuses enrolled in the National Alzheimer’s Coordinating Center (2006-2019)
  • GYeon Oh,
  • Daniela Moga,
  • Erin Abner
GYeon Oh
University of Kentucky

Corresponding Author:gyeon.oh@uky.edu

Author Profile
Daniela Moga
University of Kentucky, College of Pharmacy
Author Profile
Erin Abner
University of Kentucky, College of Public Health
Author Profile

Abstract

This study aimed to examine gabapentin utilization trends among older adults with different cognitive statuses and investigate concurrent medication use of potentially inappropriate medications. Data were extracted from National Alzheimer’s Coordinating Center Uniform Data Set (2006-2019). We estimated the yearly prevalence of gabapentin use, both overall and within subgroups defined by cognitive status [normal, mild cognitive impairment, and dementia] and demographics [age and sex] for participants aged 65+. Additionally, we assessed the prevalence of concurrent use of gabapentin with opioids, combined opioids and benzodiazepine, antidepressant, and antipsychotic. Participants reported gabapentin use increased from 2006 to 2019 in both overall and every participant subgroup. About 10-30% of gabapentin users reported to concurrently use of opioids, and more than 50% gabapentin users with dementia reported to concurrently use gabapentin with antidepressants. Given increasing use among older adults, rigorous studies are needed to examine the safety of gabapentin in this population.
15 Apr 2022Submitted to British Journal of Clinical Pharmacology
16 Apr 2022Submission Checks Completed
16 Apr 2022Assigned to Editor
02 May 2022Reviewer(s) Assigned
09 Jun 2022Review(s) Completed, Editorial Evaluation Pending
15 Jun 2022Editorial Decision: Revise Major
14 Aug 20221st Revision Received
16 Aug 2022Submission Checks Completed
16 Aug 2022Assigned to Editor
16 Aug 2022Review(s) Completed, Editorial Evaluation Pending
29 Aug 2022Editorial Decision: Accept
Jan 2023Published in British Journal of Clinical Pharmacology volume 89 issue 1 on pages 410-415. 10.1111/bcp.15532